<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02560220</url>
  </required_header>
  <id_info>
    <org_study_id>TOL-1</org_study_id>
    <nct_id>NCT02560220</nct_id>
  </id_info>
  <brief_title>MIC Cell Therapy for Individualized Immunosuppression in Living Donor Kidney Transplant Recipients</brief_title>
  <acronym>TOL-1</acronym>
  <official_title>A Single-arm Phase-I Trial for the Determination of Safety and Feasibility of the Intravenous Administration of Mitomycin C-treated Donor Peripheral Blood Mononuclear Cells (MICs) for Individualized Immunosuppression in Living Donor Kidney Transplant Recipients (TOL-1 Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Grant: German government (EXIST Forschungstransfer, TolerogenixX, 03EFB BW56)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>WiSP GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase- I clinical trial to determine safety and feasibilty of intravenous administration of
      mitomycin C-treated donor peripheral blood mononuclear cells in patients with chronic kidney
      disease stage KDIGO 4 or 5 (i.e. GFR 15-30 mL/min or &lt; 15 mL/min) who receive a kidney
      transplant from a living donor.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure is the frequency of adverse events after intravenous administration of MICs within 30 days after transplantation.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of infection</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of CMV reactivation</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with PTLD</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with delayed graft function</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with a pos. CDC and/or ELISA crossmatch</measure>
    <time_frame>day -1 before transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with DSA</measure>
    <time_frame>day -1 before transplantation and day 7 and 30 after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of biopsy-proven cellular rejection</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of biopsy-proven antibody-mediated rejection</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with stable graft function (S-creatinine &lt; 2mg/dL)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient and graft survival</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <arm_group>
    <arm_group_label>Intervention arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive MIC cell therapy together with standard immunosuppressive therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mitomycin C-induced peripheral blood mononuclear cells (MICs)</intervention_name>
    <description>MICs are given intravenously 2 or 7 days before kidney transplantation from a living donor</description>
    <arm_group_label>Intervention arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic kidney disease stage KDIGO 4 or 5

          -  First kidney transplant from a living donor

          -  Age ≥ 18 years

          -  ABO compatible

          -  CDC-PRA &lt; 20%

          -  No donor-specific antibodies

          -  Negative CDC and ELISA crossmatch

          -  Immunosuppression with cyclosporin A, EC-MPS and methylprednisolone

          -  Informed consent

          -  Adequate contraception (women with child bearing potential)

        Exclusion Criteria:

          -  Psychiatric disorder

          -  Heart failure (NYHA III or IV)

          -  Severe liver disease

          -  Active hepatitis B or C or HIV infection

          -  Active bacterial, fungal or viral disease

          -  Malignancy or malignancy in the last 5 years before screening

          -  Preexisting immunosuppression

          -  Vaccination with a live vaccine in the last 3 months before screening

          -  S/p splenectomy

          -  Substance abuse

          -  Pregnancy or lactation

          -  Women: Child/pregnancy with the intended donor

          -  Allergy against the investigational drug or part of it

          -  Other diseases that prohibit participation in the study (in the opinion of the
             investigator)

          -  Participation in an other interventional study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Zeier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heidelberg University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Morath, MD</last_name>
    <phone>+49-6221-9112</phone>
    <phone_ext>0</phone_ext>
    <email>christian.morath@med.uni-heidelberg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Morath C, Schmitt A, Zeier M, Schmitt M, Sandra-Petrescu F, Opelz G, Terness P, Schaier M, Kleist C. Cell therapy for immunosuppression after kidney transplantation. Langenbecks Arch Surg. 2015 Jul;400(5):541-50. doi: 10.1007/s00423-015-1313-z. Epub 2015 Jun 17. Review.</citation>
    <PMID>26077202</PMID>
  </reference>
  <reference>
    <citation>Kleist C, Sandra-Petrescu F, Jiga L, Dittmar L, Mohr E, Greil J, Mier W, Becker LE, Lang P, Opelz G, Terness P. Generation of suppressive blood cells for control of allograft rejection. Clin Sci (Lond). 2015 May;128(9):593-607. doi: 10.1042/CS20140258.</citation>
    <PMID>25495457</PMID>
  </reference>
  <reference>
    <citation>Dittmar L, Mohr E, Kleist C, Ehser S, Demirdizen H, Sandra-Petrescu F, Hundemer M, Opelz G, Terness P. Immunosuppressive properties of mitomycin C-incubated human myeloid blood cells (MIC) in vitro. Hum Immunol. 2015 Jul;76(7):480-7. doi: 10.1016/j.humimm.2015.06.008. Epub 2015 Jun 11.</citation>
    <PMID>26074415</PMID>
  </reference>
  <reference>
    <citation>Terness P, Oelert T, Ehser S, Chuang JJ, Lahdou I, Kleist C, Velten F, Hämmerling GJ, Arnold B, Opelz G. Mitomycin C-treated dendritic cells inactivate autoreactive T cells: toward the development of a tolerogenic vaccine in autoimmune diseases. Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18442-7. doi: 10.1073/pnas.0807185105. Epub 2008 Nov 18.</citation>
    <PMID>19017789</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2015</study_first_submitted>
  <study_first_submitted_qc>September 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2015</study_first_posted>
  <last_update_submitted>September 24, 2015</last_update_submitted>
  <last_update_submitted_qc>September 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

